| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 18, 2004
Accepted on December 14, 2004
Hereditary Endocrine Cancer Group, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain (A.Ca., S.R-LL., C.M-C., R.L., R.G., M.R.); Cancer Research UK, Department of Oncology, University of Cambridge, Cambridge, United Kingdom (A.C., F.L., B.A.J.P.); Cancer Epidemiology Service, National Center for epidemiology, Carlos III Institute of Health, Madrid, Spain (M.P.); Human Genetics Department, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain (R.L.M., J.B.); Endocrinology Service, Hospital Ramon y Cajal, Madrid, Spain (O.G-A.); Endocrinology Service, Clinica Universitaria Puerta de Hierro, Madrid, Spain (T.L-M.)
* To whom correspondence should be addressed. E-mail: mrobledo{at}cnio.es.
Medullary thyroid carcinoma (MTC) is a tumor that arises from parafollicular cells of the thyroid gland. MTC can occur sporadically (75%), or as part of inherited cancer syndromes (25%). In most cases hereditary MTC evolves from preneoplastic C-cell hyperplasia (CCH), so early detection of this pathology would evidently be critical. A recent study reports that alterations in SDHD are responsible for familial nonRET CCH. We firstly studied SDHD in two families with hereditary nonRET CCH, and found no alterations related to the inheritance of this disease. We then investigated whether the H50R variant could be a risk factor in the sporadic development of MTC both in Spanish and English patients. We found no evidence that the presence of the H50R is strongly associated with the risk of sporadic MTC, though we did observe an association with age at diagnosis of MTC in Spanish H50R carriers that we did not find in English patients. Finally, we looked for evidence of CCH or any other thyroid disease in a panel of germ-line SDH (B or D) mutation carriers, and found none. We conclude that SDHD variants do not constitute a risk factor for developing CCH, or sporadic MTC.
This article has been cited by other articles:
 |
|
 |
|
  E. Saggiorato, I. Rapa, F. Garino, G. Bussolati, F. Orlandi, M. Papotti, and M. Volante Absence of RET Gene Point Mutations in Sporadic Thyroid C-Cell Hyperplasia J. Mol. Diagn., April 1, 2007; 9(2): 214 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Zatelli, D. Piccin, F. Tagliati, A. Bottoni, A. Luchin, C. Vignali, A. Margutti, M. Bondanelli, G. C. Pansini, M. R. Pelizzo, et al. Selective Activation of Somatostatin Receptor Subtypes Differentially Modulates Secretion and Viability in Human Medullary Thyroid Carcinoma Primary Cultures: Potential Clinical Perspectives J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2218 - 2224. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
